VERA - Why Is Immunology Disease Focused Vera Therapeutics Stock Trading Higher Today? | Benzinga
Vera Therapeutics Inc (NASDAQ:VERA) announced 72-week data from the open-label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN).
Data from the OLE show the consistent and sustained reductions of serum galactose-deficient IgA1 (Gd-lgA1), hematuria, and urine protein to creatinine ratio (UPCR), as well as the stability of eGFR over 72 weeks in participants with IgAN.
After completing the 36-week Phase 2b ORIGIN trial, all participants were eligible to receive atacicept 150 mg in the OLE. ...